reports
QuickView: Changing the game in vaccines
VBI Vaccines is developing novel technologies to expand vaccine protection in large, underserved markets. VBIV’s pipeline includes a cytomegalovirus (CMV) vaccine candidate entering Phase I clinical trials (H116) and a potentially breakthrough immune-oncology glioblastoma (GBM) vaccine candidate currently generating promising preclinical data. VBIV expects to close its reverse merger with SciVac Therapeutics and complete a financing in Q116.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.